We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,191

Significant Drug Pricing Developments in July - Here’s What You Need To Know
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • USA
  • July 24 2018

In May, the Trump Administration announced its Blueprint to Lower Drug Prices and HHS Secretary Azar issued a Request for Information seeking comments


House Opioid Measure Frenzy Continues
  • Quarles & Brady LLP
  • USA
  • July 16 2018

Over a period of two weeks in June, the House passed several bills aimed at combating the ongoing opioid epidemic. Our summary of the earlier measures


FDA Regulatory and Compliance Monthly Recap June 2018
  • Loeb & Loeb LLP
  • USA
  • June 10 2018

In line with the HHS blueprint to lower drug prices and link payments for drugs to their value, the FDA finalized guidance to provide drug makers with


Washington Healthcare Update - May 21, 2018
  • McGuireWoods LLP
  • USA
  • May 21 2018

On May 17, the Energy and Commerce Committee held the second of its opioid legislation markups, clearing 32 bills. The previous markup reported out 25


GAO Releases Report Analyzing HHS-OIG Integrity Agreements Since 2005
  • Cooley LLP
  • USA
  • May 16 2018

The U.S. Government Accountability Office (GAO) released a report on May 10th characterizing over 10 years of corporate integrity agreements and


Administration presents plans to lower drug prices
  • Hogan Lovells
  • USA
  • May 14 2018

On May 11, 2018, President Trump and Department of Health and Human Services (HHS) Secretary Alex Azar delivered highly anticipated speeches regarding


Administration Releases Long-Awaited Drug Pricing Reform Plan
  • Cooley LLP
  • USA
  • May 11 2018

Today, the President and Health and Human Services (HHS) Secretary Alex Azar unveiled a 44-page Blueprint to Lower Drug Prices and Reduce


Proposed Options for Implementing the Human Subject Protections of the Research Common Rule
  • Dykema Gossett PLLC
  • USA
  • May 8 2018

The U.S. Department of Health and Human Services (DHHS), along with 15 other federal agencies, proposes to delay the effective date of sweeping


Capitol Hill Healthcare Update
  • Baker & Hostetler LLP
  • USA
  • April 23 2018

Health & Human Services (HHS) Secretary Alex Azar is recovering at his home in Indianapolis following his second hospitalization in less than a week


Will The Approval of Epidiolex Be The Start of a Domino Effect Leading to the Legalization of Marijuana in the US?
  • Taft Stettinius & Hollister LLP
  • USA
  • April 20 2018

Nearly 30 states have some sort of approval of medical marijuana or cannabis, and nine states (including the District of Columbia) have taken the